Centogene_Logo.png
CENTOGENE Receives Delisting Notice From Nasdaq
07 août 2024 18h19 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases,...
Centogene_Logo.png
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
20 juin 2024 08h00 HE | Centogene NV
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug...
Centogene_Logo.png
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
31 mai 2024 16h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
Centogene_Logo.png
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
14 mai 2024 08h30 HE | Centogene NV
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued...
Centogene_Logo.png
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
10 mai 2024 06h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
Centogene_Logo.png
CENTOGENE Receives Nasdaq Non-Compliance Notice
02 avr. 2024 16h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for...
Centogene_Logo.png
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
29 févr. 2024 17h00 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
Centogene_Logo.png
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
28 févr. 2024 06h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in...
Centogene_Logo.png
CENTOGENE Explores Strategic Alternatives
28 févr. 2024 06h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
Centogene_Logo.png
CENTOGENE Announces Voting Results of Extraordinary General Meeting
19 déc. 2023 06h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...